Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

Completed · Phase 1

Conditions studied: Advanced Cancer

In brief

This study evaluated the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-A317 in participants with advanced tumors.

Key facts

Study ID
NCT02407990
Run by
BeiGene
People needed
451
Starts
2015-06-02
Expected to finish
2020-08-12
Last updated by the study team
2021-11-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.